Amgen Inc.'s at-risk launch of biosimilar versions of Herceptin and Avastin last month was a jolt to the biosimilar community. Not only does Amgen face the threat of huge damages if it loses infringement battles with Genentech Inc., but the court's rationale for denying a preliminary injunction could change the dynamic of the patent dance.
The case shows how biosimilar litigation has evolved in the past year and raised new issues to be tackled in...






